sporine in plasma. Seven different methods were used to measure the drug in blood, and the seven methods gave seven different results when used to measure patients' samples. The results, from lowest to highest, differed by a factor of approximately 3.4. The within-assay coefficient of variation (CV) was acceptable for all methods, but the between-assay and between-center CVs were poor. HPLC gave higher CVs than did the immunoassays.
The United Kingdom Cyclosporm Quality Assessment Scheme was established in 1984. Our first report involved only 25 centers, all of which were using the original, polyclonal, nonspecific radioimmunoassay (RIA) kit manufactured by Sandoz (1). Since then the Scheme has expanded considerably, and there have been substantial developments in the methods available for the measurement of the drug.
This report covers June 1987-August 1988, a period when new specific and nonspecific RIAs based on monoclonal antibodies became available (2) , as did two nonspecific assays based on other polyclonal antisera, which were configured as an RIA and a fluorescence polarization immunoassay (3) . Using the data from the Scheme, we have attempted to describe the comparative performance of techniques currently available for measurement of cyclosporine, in terms of accuracy, reproducibility, and selectivity.
Materials and Methods
The participating laboratories received three samples each month and were expected to return the results of their measurements to the Scheme coordinators within three weeks. A summary of the results, in which the data were presented grouped by sample matrix and analytical technique, was circulated four weeks after the samples were dispatched. Centers were identified by a randomly allocated code number known only to the coordinators.
The laboratories were sent liquid samples of either whole blood or plasma, depending on the matrix used by the participating center. The source of blood and plasma was either the National Blood Transfusion Service or aliquota of pooled blood or plasma from patients receiving cyclosporine (Sandimmun#{174}; Sandoz AG, Basel, Switzerland) after renal transplantation.
The former had been screened to exclude hepatitis and HIV antibodies; technical difficulties excluded the testing of pooled blood or plasma from patients, but the patients were tested regularly for hepatitis infection. All samples were treated with sodium azide, 10 mg/L, to minimize microbial growth and beta-propiolactone, 2.5 mLIL, to inactivate HIV, as advised by the Advisory Committee on Dangerous Pathogens (4). In addition, whole-blood samples were treated with EDTA, 1 g/L, to inhibit clotting.
Unlike most drug quality-assessment schemes, most of the samples circulated in this Scheme are actual samples from patients. They therefore contain both parent drug and metabolites. There is no "gold standard" for cyclosporine measurements, so these patients' samples were not assayed before circulation and assigned a value. The range of sample types prepared was designed to testassay selectivity, withinand between-assay reproducibility, accuracy and betweenmethod differences.
To do this we used cyclosporine-free samples, repeat samples, samples containing weighed-in concentrations of cyclosponne, and pooled patients' samples.
The Scheme is open to any laboratory measuring cyclosporine, and there is no charge for membership.
Results

Centers
In June 1987 there were 102 laboratories participating in the Cyclosporin Quality Assessment Scheme. By September 1988 this number had increased to 124, drawn from 26 countries. Of the centers, 109 were in Europe, but there were participants in North and South America, the Middle East, and Australia.
Choice of Matrix
During the study period there was a continuing trend towards the use of blood, instead of plasma, as the matrix of choice for the measurement of cyclosponne. In July 1987, 23% of reported results were for plasma, but by August 1988 this percentage had fallen to 16%.
The number of results reported for plasma were too few to make meaningful comparisons between all of the analytical methods. Consequently, the results reported below refer only to the measurement of cyclosporine in blood, and the limited plasma data are dealt with separately. #{149} "High-performance" liquid chromatography (HPLC). During the 14 months covered by this report, four of these methods-Original, CycloTrac, Specific, and HPLCwere used to report results for all 42 samples. The Nonspecific assay was used for only 39, TD for 36, and CycloTrac-SP for 18.
During the study period there was a steady increase in the number of reported results obtained with specific assays (from 16 to 50) and a decrease in those obtained with nonspecific methods (from 49 to 40). In August 1988,57% of results reported for measurements in blood were obtained with specific techniques.
Cyclosporine-Free Samples, False Positives
The two cyclosporine-free samples that were circulated were reported as positive for the drug 28 times out of a total of 151 reports. The highest reported result for these samples was 84 tgfL. Table 1 summarizes the false-positive reports.
AnalyticalVariables
Within-assay variation. This was assessed by circulating three identical samples, drawn from pooled patients' samples, in the same month. Most of the centers, 56/89, obtained a coefficient of variation (CV) 5%. However, 14 of the 89 produced CVs >11%; of these, six had CVs >15%. Table 2 shows the distribution of precision by method.
Between-assay variation.
This was measured at three concentrations in three pooled patients' samples in three consecutive months. As measured by the Original method, these pooled patients' samples had cyclosporine concentrations of -200, 400, and 800 g/L for the low, medium, and high pools, respectively. The median CV for CYCLO-Trac assay was consistently better and that for HPLC was consistently worse than was the case for the other three methods (Table 3) . Accuracy. Measurement accuracy was assessed by analyzing cyclosporine-free samples to which the drug had been added to give eight known concentrations in the range 25 to 1000 gJL. The results are shown graphically in Figure 1 .
Between-method agreement. Figure 2 shows the relative response of the seven assay methods for the analysis of 34 samples of pooled patients' blood. The figure uses both the original and HPLC assays as the 100% references, and the results are presented as the mean and 95% confidence intervals relative to these methods. The relative response was calculated for each method and sample as: Relative response = (100 x method mean)/reference assay mean. 
Between-center,
within-method agreement. For each sample circulated, the agreement between centers using a particular method can be assessed by the method CV. Table  4 lists, by method, the median between center CV, and the interquartile range, for the 34 pooled patients' samples circulated during the 14 months. Therefore, this table sununai-izes how well centers using the same assay agreed: the smaller the CV, the better the between-center agreement. It might be thought that precision varies with concentration, but plots of CV vs concentration did not support this assumption over the concentration range of the circulated samples. Measured value 500 iig/L
Plasma Measurements
Discussion
During the study period the number of centers in the Cyclosporin Quality Assessment Scheme increased steadily. During this time the trend was, as suggested in the AACC guidelines (5) , towards the use of blood instead of plasma as the matrix of choice, and towards a specific rather than a nonspecific assay for the therapeutic momtoring of cyclosporine. Despite the number of new, professionally prepared assay methods available for cyclosporine measurement, the between-center variation remains high. The median between-center CVs ranged from 13% to 21%, depending on the assay method used. Although the within-assay CV was acceptable for all the assay methods, between-assay precision was poor. Of the four methods tested-Original, CY-CLO-Trac, Specific, and HPLC-only for CYCLO-Trac did the majority of centers report CVs of <12%. The better between-assay CV of this method is probably attributable to the inclusion of prediluted standards within the kit.
The number of centers in the Scheme is now large enough to allow a meaningful comparison of the assay techniques used. The accuracy of the seven major methods for cyclosporine measurement, as assessed by blank samples to which cyclosporine had been added, was good.
However, some assays showed a loss of accuracy at low drug concentrations and some laboratories were unable to recognize their lower limit of detection. Also, although the able, the frequency and magnitude of the results were an improvement over previous findings (1, 6 differences in results by the nonspecific methods could be expected, given that the spectrum of crossreactivity of the antibodies differs in each case, the lack of agreement between the specific methods was unexpected, a finding that is at variance with published data from single centers (7-9). Since these data were collected, the INCStar
Corp. have made known that they have recalibrated the standards in their CYCLOTrac SP kit against a USP standard. As a result, the assigned values for their standards will be decreased by approximately 15%, thus minimizing the differences between HPLC and this immunoassay noted in our quality-assessment data. Further study, involving a wider selection of patients' material, will be required, to establish whether the differences noted here between the specific RIAs and HPLC are a sustained finding and whether they are statistically or clinically significant. However, our observations do reinforce the Upper qr need for continuing quality-assessment as methods for measuring cyclosporine become more diverse and its routine measurement more widespread.
The Scheme receives the financial support of Sandoz AG, Basel, Switzerland.
